Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F055 - Late-breaking Research: Basic Science/Cutaneous Oncology/Pathology

Saturday, March 2; 9:00 AM - 11:00 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Describe ground-breaking scientific developments in dermatologic research.
  • Evaluate and apply information from recent investigations to clinical practice.

Description

Researchers can submit abstracts describing their most recent unpublished results. After a competitive review, the top scoring studies will be invited to discuss their findings in a brief oral presentation during one of the themed sessions. This year, there will be three Forums (clinical/pediatric dermatology, surgery/procedural dermatology and basic science/dermatopathology) and a new Clinical Trials Symposium. Together, these sessions will highlight the latest ground-breaking observations in all aspects of dermatological research.

Disclosures

  • Beroukhim, Kourosh, MD: no financial relationships exist with commercial interests.
  • Greenhaw, Bradley Noel, MD: Castle Biosciences, Inc – A(H), SP(NC);
  • Gupta, Deepti, MD: no financial relationships exist with commercial interests.
  • Hong, Kathy Chien-Hui, MD, PhD: no financial relationships exist with commercial interests.
  • Kolodney, Michael S., MD, PhD: no financial relationships exist with commercial interests.
  • Krueger, James G., MD, PhD: AbbVie – C(H); Akros Pharma, Inc. – I(Grants/Research Funding); Allergan, Inc. – C(H), I(Grants/Research Funding); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding); Arena Pharmaceuticals – C(H); Aristea – C(H); Asana Biosciences, LLC – C(H); Aurigene Discovery Technologies, Inc. – C(H); Avillion – I(Grants/Research Funding); Biogen – C(H), I(Grants/Research Funding); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Botanix Pharmaceuticals – I(Grants/Research Funding); Bristol-Myers Squibb – C(H), I(Grants/Research Funding); Celgene – C(H), I(Grants/Research Funding); Eli Lilly and Company – C(H), I(Grants/Research Funding); Escalier – C(H); Exicure – I(Grants/Research Funding); Incyte Corporation – I(Grants/Research Funding); Innovaderm Research Inc. – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H), I(Grants/Research Funding); Leo Pharma Inc – I(Grants/Research Funding); Leo Pharma Inc. – C(H), I(Grants/Research Funding); Menlo Therapeutics – C(H); Nimbus Therapeutics – C(H); Novan – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H); Parexel – I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); Regeneron – I(Grants/Research Funding); Sanofi US Services – C(H); Sienna Biopharmaceuticals – C(H), I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H); UCB – C(H), I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – C(H); Vitae Pharmaceuticals – I(Grants/Research Funding);
  • Lee, Michael: no financial relationships exist with commercial interests.
  • Morgan, Frederick: no financial relationships exist with commercial interests.
  • Neumann, Avidan: no financial relationships exist with commercial interests.
  • Nghiem, Paul, MD, PhD: Bristol-Myers Squibb – I(Grants/Research Funding); EMD Serono – C(Fees); Merck & Co., Inc – A(H); Sanofi/Regeneron – A(H);
  • Ruiz, Emily S, MD: no financial relationships exist with commercial interests.
  • Smieszek, Sandra: Vanda Pharmaceuticals Inc. – E(S);
  • Tsao, Hensin, MD, PhD: Asana Biosciences, LLC – I(Grants/Research Funding); Epiphany Dermatology – A(H); Massachusetts General Hospital – E(S); Relay Therapeutics – I(Grants/Research Funding); UpToDate, Inc. – O(H); Worldcare Clinical, LLC – C(H);
  • Werbel, Tyler, MS: no financial relationships exist with commercial interests.
Schedule
Saturday, March 2
9:00 AM
Dr. Gupta / Declining Incidence of Invasive Melanoma in Adolescents and Young Adults in the United States
9:10 AM
Dr. Beroukhim / Relationship of Cutaneous and Noncutaneous Malignant Melanoma in Persons with Multiple Primary Tumors
9:20 AM
Dr. Greenhaw / Meta-analysis of the Prognostic 31-gene Expression Profile Test in 1261 Cutaneous Melanoma Cases
9:30 AM
Lee / Characterizing Trends in Utilization of Mohs Micrographic Surgery for Melanoma in the United States
9:40 AM
Morgan / The Brigham and Women’s Hospital Tumor Classification System for Basal Cell Carcinoma
9:50 AM
Dr. Ruiz / Trends in Skin Cancer Treatment Costs in Massachusetts, 2012-2015
10:00 AM
Hong / Cancer Risk in Patients with Keloids: A nationwide population-based cohort study
10:10 AM
Neumann / Staphylococcus Dysbiosis Correlates of Success of Treatment of Atopic Dermatitis with the JAK/SYK Inhibitor ASN002
10:20 AM
Smieszek / Whole Genome Sequencing Reveals Novel Rare Loss-of-function Variants in the Epidermal Differentiation Complex as Predisposing Factors to Atopic Dermatitis
10:30 AM
Dr. Krueger / The Therapeutic Efficacy of BI 655130, an Anti-interleukin-36 Receptor Antibody, in Patients with Acute Generalized Pustular Psoriasis is Associated with the Downregulation of Inflammatory and Tissue
10:40 AM
Werbel / Botulinum Toxin Blocks Mast Cells and Prevents Rosacea Like Inflammation
10:50 AM
Dr. Kolodney / Trichilemmal (Pilar) Cysts are Caused by Two “Hits” to the PLCD1 Gene: One inherited and one somatic
Event Details
  • Date
    Saturday, March 2
  • Time
    9:00 AM - 11:00 AM
  • Location
    Room 101
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
Speakers
  • Avidan Neumann
  • Bradley Noel Greenhaw, MD, FAAD
  • Deepti Gupta, MD, FAAD
  • Emily S Ruiz, MD, FAAD
  • Frederick Morgan
  • James G. Krueger, MD, PhD, FAAD
  • Kathy Chien-Hui Hong, MD, PhD
  • Kourosh Beroukhim, MD
  • Michael Lee
  • Michael S. Kolodney, MD, PhD, FAAD
  • Paul Nghiem, MD, PhD, FAAD
  • Sandra Smieszek
  • Tyler Werbel, MS